Long non-coding RNA FAM84B-AS promotes resistance of gastric cancer to platinum drugs through inhibition of FAM84B expression.
To investigate the expression and significance of the long non-coding RNA (lncRNA) FAM84B-AS in gastric cancer tissues and its effect on platinum drug resistance in gastric cancer. (1) The expression of FAM84B-AS was detected in samples from 228 cases of fresh gastric cancer to analyze its association with clinical data and gastric cancer prognosis. (2) An lncRNA interference cell line model was established and used to study the effects of FAM84B-AS on the malignant biological behaviors of gastric cancer cells and platinum drug resistance at the cellular level. (3) The mechanisms underlying the effect of FAM84B-AS on gastric cancer were investigated using Western blotting. (1) FAM84B-AS was closely associated with the differentiation level, T stage, and N stage of gastric cancer and could be used as an independent risk factor of the prognosis of gastric cancer. (2) FAM84B-AS interference significantly inhibited the proliferation and invasion abilities of gastric cancer cells and significantly increased the percentage of apoptosis. FAM84B-AS could partially restore the sensitivity of drug resistant cells to platinum drugs. The above results were also confirmed in in vivo studies. (3) Western blot results demonstrated that FAM84B-AS interference could activate apoptosis signaling pathways in gastric cancer cells to promote apoptosis in gastric cells. FAM84B-AS could be used as a molecular marker of the malignancy of gastric cancer and offers a certain predictive function for gastric cancer prognosis. FAM84B-AS promotes gastric cancer proliferation through inhibition of apoptosis signaling pathways and promotes drug resistance of gastric cancer cells to platinum drugs through its apoptosis-inhibiting functions.